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Abstract 
 
Objectives. Treat-to-target recommendations have identified ‘remission’ as a target in systemic 
lupus erythematosus (SLE) but recognize that there is no universally accepted definition for this. 
Therefore, we initiated a process to achieve consensus on potential definitions for remission in SLE.  
Methods.  An international task force of sixty specialists and patient representatives participated in 
preparatory exercises, a face-to-face meeting, and follow-up electronic voting. The level for 
agreement was set at 90%. 
Results.  
The task force agreed on eight key statements regarding remission in SLE and three principles to 
guide the further development of remission definitions: 
1. Definitions of remission will be worded as follows: Remission in SLE is a durable state 
characterized by …………………. (reference to symptoms, signs, routine labs).   
2. For defining remission a validated index must be used, e.g., clinical-SLEDAI = 0, 
BILAG2004 D/E only, clinical ECLAM =0; with routine laboratory assessments included, 
and supplemented with Physician Global Assessment. 
3. Distinction is made between remission off and on therapy: Remission-off-therapy requires the 
patient to be on no other treatment for SLE than maintenance antimalarials; and Remission-
on-therapy allows patients to be on stable maintenance antimalarials, low-dose 
corticosteroids (prednisone <5 mg/d), maintenance immunosuppressives and/or maintenance 
biologics.   
The task force also agreed that the most appropriate outcomes (dependent variables) for testing the 
prognostic value (construct validity) of potential remission definitions are: Death, Damage, Flares, 
and measures of Health-related quality of life.  
Conclusion. The work of this international task force provides a framework for testing different 
definitions of remission against longer-term outcomes.  
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Introduction 
Outcomes in systemic lupus erythematosus (SLE) have improved considerably over the past decades. 
For the most widely studied specific organ involvement in SLE, lupus nephritis, results from clinical 
trial follow-up studies demonstrate that the long-term renal survival in this condition has now 
improved to greater than 90%.[1] However, not all outcomes in SLE show the same favorable trends. 
Most notably the overall health-related quality of life (HR-QoL) for patients with SLE remains 
reduced.[2]. This and other considerations prompted the initiation of the Treat-to-Target for SLE 
(T2T/SLE), initiative which over the past several years established an international consensus on the 
approach to the therapy of SLE based on 1) identifying an appropriate target for each patient; 2) 
initiating treatment steps to try to achieve this target; 3) assessing the target; and 4) adjusting the 
therapeutic approach, if necessary. These elaborations led to the T2T/SLE recommendations 
published in 2014.[3] One of the most significant targets in SLE was identified as “remission of 
systemic symptoms and organ manifestations”. However, it was recognized by the panel that no 
generally accepted definition of remission in SLE exists today. Such a definition could be important 
for basic, clinical and epidemiological studies and clinical trials in lupus, but also for clinical 
practice. The literature on this topic demonstrates that many clinical trials and observational studies 
have used a large number of different ad hoc definitions of remission; many of these were reviewed 
in a recent study.[4] Consequently, the T2T/SLE panel identified the definition of remission as a 
research priority for SLE. In response, an initiative was undertaken in order to achieve consensus in a 
large multiparty international task force on potential definitions of remission in SLE (DORIS).  
 
Methods 
An international task force consisting of rheumatologists, nephrologists, dermatologists, clinical 
immunologists and patient representatives, totaling 60 individuals, was convened. In March 2014, a 
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preliminary meeting was held by a steering committee consisting of 15 of these representatives. The 
steering committee identified four domains critical to further development of remission definitions; 
ten preliminary statements regarding remission that were felt to be uncontroversial; key 
controversies; and a set of proposed topics for further discussion. During the following 4-month 
period, the ten preliminary statements were presented to the full task force electronically, deliberated 
upon by email, and then subjected to formal electronic voting. High-level agreement was readily 
achieved for eight of these, whereas two were placed on the agenda for the subsequent consensus 
conference. Moreover, an additional number of key topics were identified during these deliberations 
that were to be dealt with more thoroughly at the face-to-face meeting.  
In August 2014, a consensus conference took place where a large majority of the full task force was 
present. The explicit goal of this consensus conference was to establish guiding principles for 
working towards a definition of remission in SLE and to formulate proposed definitions that would 
be amenable to scientific testing. During this meeting, formal votes were taken on a range of points. 
The level for agreement was set at >90%.   
The procedure was informed by the results of the systematic literature review that was carried out in 
the context of the ‘Treat-to-target in SLE’ project [3] and was modified and updated in September 
2015. We focused on two of the twelve original topics of interest that were more relevant to the 
present study, namely topic #2 (“Have any definitions for low disease activity and remission, -both 
global and organ-specific-, been validated as surrogates of therapeutic success against damage 
accrual, mortality, and QoL in SLE?”) and topic #5 (“Is sustained reduction of disease activity or 
prevention of flares, -both general and organ-specific-, an achievable goal in SLE?”).[3] The 
literature search was repeated in September 2015 by author GB to include more recently published 
literature. The PubMed database was searched using index terms and all English-language human 
studies were evaluated based on the title, abstract and/or full-text. For the purpose of the present 
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study, we report on the systematic literature review results relevant to remission only, which were 
published since the year 1990 and included ≥70 SLE patients. 
 
Results 
Domains considered critical for defining remission in SLE. Four domains critical for defining 
remission in SLE were identified: clinical disease activity, serological activity, duration, and 
treatment. Within each of these domains a number of key issues were identified and these form the 
basis of the work described here.  
 
Preliminary statements on remission in SLE.  
Ten statements, considered highly relevant for developing a definition of remission and expected to 
be uncontroversial, were prepared by the steering committee and subjected to electronic voting by 
the task force. Eight of these statements readily achieved a high level of consensus (>90%) and are 
shown in table 1.  
 Statement % in favor 
1 Remission is a desirable outcome for the patient with SLE 100% 
2 Remission in SLE includes, at the very least, the absence of 
symptoms and signs of SLE. 
100% 
3 Remission in SLE is not the same as a cure. 100% 
4 Remission in SLE is not the same as low disease activity.  93% 
5 Remission is a state that, if sustained, is associated with a low 
likelihood of adverse outcome. 
100% 
6 “Serological activity” in SLE generally refers to the presence of 100% 
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anti-DNA antibodies and/or hypocomplementemia. 
7 Treatment with antimalarials does not preclude the patient from 
being considered to be in remission. 
98% 
8 Treatment with moderate- or high-dose steroids does preclude the 
patient from being considered in remission.  
98% 
 
Table 1. Preliminary statements on remission in SLE. Out of ten statements selected by the steering 
committee, eight achieved >90% agreement on electronic voting by the entire task force. Two 
statements (“A definition of remission SLE must be reasonably consistent with the use of this term in 
the literature” and “Durability in time can be added to any definition of remission in order to define a 
‘durable remission’ but need not be included in the definition of remission itself”) did not achieve 
consensus and were discussed further at the face-to-face meeting.  
 
Therefore, remission is identified as a desirable outcome for patients with SLE with, -at the very 
least-, the absence of major symptoms and signs of SLE. Remission is conceived of in terms 
different from a cure, yet it is also regarded as meaningfully different from a low disease activity 
state, including the lupus low disease activity state (LLDAS) that has recently been proposed by the 
Asia-Pacific Lupus Collaboration.[5] Perhaps most critically for future work in this area, it is 
recognized that remission, like LLDAS, has to be a state that, if sustained, is associated with a low 
likelihood of adverse outcome. To this end, the systematic literature review identified a number of 
observational studies in patients with lupus nephritis, which illustrate that attainment of (complete) 
renal remission (or response) (typically defined as a very low level of proteinuria, with normal or 
stable renal function, with or without inactive urine sediment) is associated with favorable long-term 
patient and renal outcomes (Table 2). Similarly, in general SLE, three retrospective cohort studies 
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have suggested that patients who achieve disease remission have significantly lower rates of damage 
accrual or mortality after follow-up.  
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Author 
(ref.) 
N Remission definition(s)  Remission 
achieved (%) 
Association of remission with outcomes 
General SLE    
Drenkard 
[6] 
667 ≥1 year of clinically inactive disease (serological 
activity allowed) that permitted withdrawal of all 
lupus drugs 
23.4% 12.5-fold reduced risk for death (follow-up 11.6 ± 6.0 
years), after controlling for effects of renal disease 
and thrombocytopenia 
Nossent 
[7] 
200 Physician judgment (not otherwise specified), 
assessed during the first year of disease 
27.5% Lower annual relapse rates, lower average SLEDAI, 
lower cumulative SDI scores at the end of 5-year 
follow-up  
Zen [8] 224 ≥5 years complete remission with SLEDAI-2K=0 
(HCQ allowed) or clinical remission with clinical 
SLEDAI-2K=0 (serological activity allowed) off-
steroids or on low-dose steroids (HCQ/ISTs 
allowed) 
7.1% (complete 
remission), 
14.7% (off-
steroids), 15.6% 
(on steroids) 
Damage accrual rates (end of 5-year follow-up): 
18.8% (complete remission), 18.2% (off-steroids), 
37.1% (on steroids), and 51.4% (no remission) 
Medina-
Quiñones 
[9]  
532 ≥3 years with BILAG C, D or E, no serological 
activity, off-steroids, off-immunosuppressives 
(HCQ/NSAIDs allowed) 
14.5% Lower mortality rates (5.2% vs. 13.4%; median 
follow-up 12 years) 
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Lupus nephritis    
Moroni 
[10] 
70 CRR: UPr* <0.2, normal renal function 38.5% (at last 
follow-up) 
CRR was associated with fewer renal flares, better 
outcome of renal flares 
Mok [11] 183 CRR: UPr <0.3, normal SAlb, normal renal 
function, assessed at the end of first year of therapy 
64% Lack of CRR was associated (RR 9.9) with 
development of ESRD (mean follow-up 181 months) 
Korbet 
[12] 
86 CRR: SCr ≤1.4 mg/dl, UPr ≤0.33, attained within 5 
years of entering the study. See also refs [13], [14] 
43% CRR was associated with reduced risk of progression 
to ESRD (HR 0.12), increased rates of patient 
survival at 5 and 10 years (follow-up 120 ± 65 
months) 
Illei [15] 145 CRR: SCr <130% of the lowest level during 
treatment, UPr <1, inactive urine sediment, off IST 
(HCQ and prednisone ≤10 mg/day allowed), for ≥6 
months 
50.3% Lack of CRR was associated with increased risk for 
severe nephritic flare (LR 5.7) and progression to 
ESRD (LR 7.0) (median follow-up 116 to 123 
months) 
Hill [16] 71 CRR: SCr ≤123 μmol/L, UPr ≤0.33  N/D Lack of CRR was associated with decreased 10-year 
survival rates from doubling of SCr 
Mok [17] 189 CRR: stabilized/improved SCr, UPr <1, improved 55% Lack of CRR was associated with increased risk (HR 
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serum C3 for ≥6 months, assessed at the end of IST 4.5) for development of ESRD (mean follow-up 96.5 
months) 
Mok [18] 268 Same as in [17] 59% Lack of CRR was associated with increased risk (HR 
4.5) for adverse outcome (doubling of SCr or ESRD 
or patient death) 
Moroni 
[19] 
93 CRR: SCr <1.2 mg/dL, stable or 25% increase of 
baseline CrCl, UPr <0.2, inactive urine sediment 
82% (63.4% at 
last follow-up) 
Lack of CRR was associated (RR 4.3) with 
development of chronic renal insufficiency (median 
follow-up 181 months) 
Mak [20] 149 CRR: stabilized/improved SCr, improved serum 
complement, UPr <1, inactive urine sediment for ≥6 
months, assessed at the end of first year of therapy 
60.4% Lack of CRR was associated with renal damage 
(mean follow-up 80 months) 
Lee [21] 77 CRR: SCr <1.2 mg/dl, UPr <0.2, inactive urinary 
sediment, for ≥6 months 
52% Lack of CRR was associated with development of 
chronic renal insufficiency and/or death (follow-up 
8.3 ± 4.4 years) 
Sun [22] 100 CRR: UPr ≤0.4, normal urinary sediment, normal 
SAlb, normal SCr  
58% Lack of CRR was associated with ESRD (median 
follow-up 60 months) 
Ayodele 105 CRR: stable [±25%] renal function, UPr <0.2, 44.8% CRR was associated with higher mean survival time  
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[23] assessed at the end of first year of therapy 
So [24] 117 CRR: SCr ≤1.4 mg/dl, UPr ≤0.5, inactive urine 
sediment, assessed after 6 months of therapy 
50.4% CRR was associated with reduced risk for subsequent 
renal flares and chronic renal failure (mean follow-up 
66–76 months) 
Reich [25] 98 CRR: SCr ≤120 mmol/l (1.4 mg/dl), UPr <0.3  
 
74.5% Lack of CRR was associated with faster GFR decline 
(follow-up 12.4 ± 8.4 years) 
Alsuwaida 
[26] 
77 CRR: SCr ≤125 μmol/L, UPr ≤0.33  41.6% CRR was associated with higher renal survival rate at 
10 years. Lower risk for doubling of SCr 
Dhir [27] 188 UPr reduction by ≥50% to <2, inactive urine 
sediment, normal SCr (≤1.5 mg/dl), assessed at the 
end of first year 
54.6% § Lack of remission was associated (HR 13.8) with 
chronic renal failure or death (median follow-up 6 
years) 
Moroni 
[28]  
103 CRR: SCr <1.2 mg/dL, stable or 25% increase of 
baseline CrCl, UPr <0.2, inactive urine sediment  
70.9% CRR was associated with good renal outcome (no 
chronic renal insufficiency) (follow-up 156 ± 105 
months)  
 
Mahmoud 
[29] 
135 CRR: SCr ≤1.2 mg/dl, and 25% increase of baseline 
CrCl if abnormal, or stable value if abnormal at 
59.3% Lack of CRR in the first year was associated with 
adverse outcome (death, ESRD or doubling of SCr) 
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baseline, UPr <0.2, inactive urine sediment 
Fernandes 
das Neves 
[30]  
105 CRR: UPr <0.2, negative anti-dsDNA antibodies, 
normal C3, and normal SCr, for ≥5 consecutive 
years 
38.1% CRR was associated with preservation of normal 
renal function (80% vs. 43%) and reduced mortality 
(0% vs. 22%) compared to partial/no remission group 
(follow-up 13.7 ± 14.1 years) 
Koo [31] 193 CRR: UPr <0.3, for ≥6 months 42.5% CRR was associated with reduced risk of mortality 
and ESRD (follow-up 158 ± 70 months) 
Dall’Era 
[32] 
76 Different sets of response criteria based on a range 
of cut-offs of UPr, SCr, and RBCs at 3, 6, and 12 
months. Best criterion was UPr <0.8 at 12 months 
59.2% Sensitivity 81% and specificity 78% for favorable 
long-term (7 years) renal outcome (SCr ≤1.0 mg/dl). 
The LUNAR study remission criterion (UPr ≤0.5, SCr 
±15% of baseline, inactive urine sediment) had 32% 
sensitivity, 91% specificity 
Tamirou 
[33] 
104 Different sets of CR criteria based on levels of UPr, 
Scr, and urinary RBCs at 3, 6, and 12 months. Best 
criterion was UPr ≤0.5 at 12 months 
49.0% Positive predictive value 92% for achieving good 
long-term renal outcome (SCr ≤120% of baseline 
value) after median 110 months 
Tamirou 
[34] 
80 Subgroup analysis of [33]. Different sets of 
response criteria based on a range of cut-offs of 
63.8% Sensitivity 71% and specificity 75% for favorable 
long-term (7 years) renal outcome (SCr ≤1.0 mg/dl). 
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UPr, SCr, and RBCs at 3, 6, and 12 months. Best 
criterion was UPr <0.7 at 12 months 
 
Table 2. Validation of published definitions of disease remission against outcomes in SLE (studies with n ≥70 patients). 
* Proteinuria (UPr) assessed by 24-hr urine collection and/or urine protein-to-creatinine ratio 
§ n = 71 out of 130 with available records 
Abbreviations: CRR, complete renal remission (or response); UPr, proteinuria; SCr, serum creatinine; GFR, glomerular filtration rate; CrCl, 
creatinine clearance; RBCs, red blood cells; HR, hazard ratio; ESRD, end-stage renal disease; SDI, Systemic Lupus International Collaborating 
Clinics/American College of Rheumatology (ACR) Damage Index SLICC group damage index; SAlb, serum albumin; IST, immunosuppressive 
treatment; HCQ, hydroxychloroquine; N/D, not described. 
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Specific agreement was also achieved on the definition of “serological activity” where it was agreed 
that there was sufficient support in the literature pertaining to the presence of anti-DNA antibodies 
and/or hypocomplementemia (defined as above or below the upper limit of normal value for the local 
laboratory, respectively), but without reference to other autoantibodies. The task force discussed 
whether definitions of remission should distinguish patients who are serologically active from those 
who are serologically inactive, as the former are much more likely to experience subsequent flare.[4, 
9] No consensus was reached on that statement and the task force suggested to test each of the 
clinical criteria with and without serology, in order to determine the usefulness of the latter and 
whether it adds to the construct validity of each definition. 
Finally, there was consensus in the task force that treatment with anti-malarials does not preclude the 
patient from being considered to be in remission, even though it is somewhat paradoxical to say “off-
treatment” when someone is, in fact, taking a medication. However, this step was strongly supported 
by the task force in respect of the widely-held view that anti-malarials are often considered long-term 
maintenance therapy for patients with SLE even if they have achieved remission. Benefits of such 
treatment are believed to extend beyond flare prevention and disease control, and it was therefore felt 
incorrect to imply that these medication should be discontinued. The task force does recognize that 
antimalarials have immunomodulatory effects, and that therefore studies done on patients in 
remission “off treatment” (by the above definition) may in some instances have to distinguish clearly 
between those patients who are and who are not taking antimalarials. This would perhaps seem most 
important for studies of an immunological or pathophysiological nature. A similar arguments does of 
course also apply to medications that do not fall in the above categories but that have or may have 
immunomodulatory properties, such as statins and vitamin D.     
It was also agreed upon by all that patients who are treated with moderate- or high-dose 
glucocorticoids cannot be considered to be in remission, even if they would fulfill other criteria for 
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remission. The main argument for this is the well-established adverse health consequence of long-
term moderate- to high-dose glucocorticoid treatment.  
Two statements were felt to be uncontroversial by the steering committee but did not achieve >90% 
agreement in the larger task force. One of these, “A definition of remission in SLE must be 
reasonably consistent with the use of this term in the literature” was intended by the steering 
committee as indicating that a definition of remission must be aligned with what historically has 
been considered to be a remission. However, this statement was felt to be a bit too circular by some, 
given that the literature is divided on the definition of remission.  
The statement “Durability in time can be added to any definition of remission in order to define a 
‘durable remission’ – but need not be included in the definition of remission itself.” achieved 86% 
agreement by pre-meeting electronic voting. Notably, although a few of the published definitions 
included in Table 2 have incorporated a “duration” component (ranging from 6 months to 5 years), 
the majority to the studies has not examined the prognostic importance of duration of remission 
against long-term patient outcomes. When discussed face-to-face by the full task force, an increasing 
number of delegates were unable to support this statement. After discussion, the vote was 65% in 
favor – not sufficient to declare consensus. The main arguments for and against this statement, as 
they were discussed during the meeting, are given in Table 3: 
 
In favor of the original statement 
(i.e, the definition of remission does not  
have to include the duration) 
Against the original statement 
(i.e., the definition of remission does have to 
include the duration) 
 Definitions of remission in other 
autoimmune diseases, including 
 As SLE can be remitting-relapsing,[37] 
for a patient to be in remission at one 
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rheumatoid arthritis [35] and Crohn’s 
disease,[36] do not include durability 
specific point in time may not be 
clinically relevant 
 Including durability in the definition 
itself would severely limit the use of the 
definition as an outcome in clinical trials 
 Remission for only a short period of time 
has little relevance in SLE 
 Duration can always be added to the 
analyses in which the definition is used  
 
 
Table 3. Arguments for and against the statement “Durability in time can be added to any definition 
of remission in order to define a ‘durable remission’ but need not be included in the definition of 
remission itself.”  
 
The framework for a definition.  
The task force discussed what form a definition of remission in SLE should take. A literature search 
on this topic identified many observational studies and clinical trials that used a large number of 
different ad hoc definitions of remission in general SLE (Appendix Table 1) and in lupus nephritis 
(Appendix Table 2). After extensively reviewing various options, and with particular attention to the 
discussion described above regarding duration, the following three key principles were agreed upon 
(summarized in Table 4): 
 
Key principles for defining remission in SLE Agreement 
1.  Definitions of remission in SLE will be worded as follows: Remission 93%  
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in SLE is a durable state characterized by …………………. 
(reference to symptoms, signs, routine labs) 
o Requirement for serology may be added 
(2 abstained) 
2.  For defining remission in SLE, a validated index must be used 
o Suggested indices are: clinical SLEDAI = 0; BILAG 2004 D 
or E only; clinical ECLAM = 0  
o These must be supplemented by the Physician’s Global 
Assessment being below an appropriate threshold (e.g., <0.5 
on a 0–3 scale) 
98% 
3.  A distinction will be made between remission off therapy and 
remission on therapy 
o Remission off therapy requires the patient to be on no other 
treatment for SLE than maintenance antimalarials 
o Remission on therapy allows patients to be treated with 
maintenance antimalarials, stable, low-dose glucocorticoids 
(e.g., prednisone <5 mg/day), maintenance 
immunosuppressives and/or stable (maintenance) biologics 
100%  
(3 abstained) 
 
Table 4. The task force’s three key recommendations for defining remission in SLE. 
 
1. The task force achieved consensus (93%) for the principle that remission in SLE will be defined 
using the following format: 
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“Remission in SLE is a durable state characterized by …. (followed by a reference indicating the 
absence of symptoms, signs or abnormal labs)”.  
It can be recognized that this definition is to some extent a compromise because it does not 
specify the length of time during which a remission would have to be sustained in order to 
qualify. This is a direct result of the fact that no agreement on this could be achieved and that the 
task force felt that further scientific studies are needed to define the optimal duration for any 
statement of remission in SLE. A further area of uncertainty was whether the absence of active 
serology would be required and yet again it was felt that this could be investigated in the future. 
It should therefore also be recognized that ‘abnormal labs’ in the above statement refers to 
routine laboratory assessments and not necessarily to anti-DNA antibodies or complement levels.  
 
2. The task force spent much time on finding correct formulations for defining the absence of 
clinical signs and symptoms for use in a definition and agreed, in the end, that for this a validated 
index must be used (98% agreement). The task force specifically suggests that the following can 
be considered: clinical SLEDAI = 0; BILAG 2004 D or E categories only; or clinical ECLAM = 
0. Furthermore, it is recommended that each of these indices is supplemented with the 
requirement for the Physician’s Global Assessment (PhGA) to be below a certain level: in the 
case of a PhGA ranging from 0 to 3 that should be < 0.5. Note that in all instances the term 
“clinical” for SLEDAI and ECLAM refers to symptoms, signs and routine laboratory testing and 
disregarding only the points that can be given for the presence of anti-DNA antibodies and/or 
low complement. The task force also discussed the possibility of defining remission in terms of 
specific symptoms and signs, such as was done for the proposed definition of remission in 
pediatric SLE, where certain symptoms and signs are “allowed” for patients with SLE who are 
nevertheless considered to be in remission.[38] Although a minority of participants favored this 
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approach, there was a more widespread feeling that not using validated indices would to some 
extent be retrograde, and that practice in various research settings would also increasingly be 
dominated by the use of such indices. 
 
 
3. The task force recommends that a distinction should be made between “remission off therapy” 
and “remission on therapy” (100% agreement). These two descriptors were chosen in preference 
to many other suggested terms, some of which are: “complete” versus “partial” remission; 
“complete” versus “clinical” remission; “remission” versus “lupus under control” or “inactive 
disease”. While there are subtle nuances differentiating between these possibilities, it was 
considered important to simplify this matter and to strictly limit the number of definitions to two 
levels of remission.  
In this regard, it is also important that “off-therapy” will mean that the patient is on no other 
immunomodulatory treatment for SLE than possibly anti-malarials. As pointed out earlier, for 
some studies, in particular mechanistic investigations, the immunomodulatory properties of 
antimalarials must be considered, and in general accurate recording of all medications is 
recommended.  
“Remission-on-therapy” will allow some, but not all medications. Specifically, stable 
immunosuppressives, including biological immunomodulators, are allowed within this level of 
remission. It was noted that definitions of remission in other autoimmune diseases, including 
rheumatoid arthritis[35] and Crohn’s disease[36], do not exclude the chronic use of specific 
antirheumatic medications, immunosuppressives, or biologics. Likewise, these definitions do not 
limit the use of glucocorticoids. However, in SLE a major contributor to long-term damage and 
other adverse outcomes is the chronic use of glucocorticoids, and the task force felt that for the 
patient to be declared in “remission-on-treatment” the highest allowable dose of glucocorticoids 
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is 5 mg/day prednisone (or equivalent). Prednisone dose thresholds associated with protection 
from treatment-related harm are currently being studied by several groups and data from those 
studies should further inform the selection of a threshold glucocorticoid dose in a definition of 
remission-on-therapy. 
 
Further development of the most appropriate definition of remission. The task force discussed in 
what manner a future definition of remission in SLE could be most thoroughly established.  
It was agreed upon by voting that for testing the construct validity of each potential remission 
definition the most appropriate outcomes are death, damage, lupus flares, and HR-QOL measures 
(100% agreement).  
Thus, the task force indicated that any definition of remission in SLE must be tested in terms of the 
degree to which it correctly identifies patients whose future disease course will be better in these four 
outcomes. Though mortality remains a key outcome, it is unlikely that many studies will be able to 
identify this as a differentiating factor. Damage as measured by the SLICC damage index (SDI) [39] 
will most likely be the most effective way of ascertaining the construct validity of a definition of 
remission, as has been provisionally demonstrated for the definition of LLDAS. However, the 
occurrence of flares, especially severe flares, that can be measured by a variety of instruments,[40-
42] and measures of HR-QoL will also be important in determining which potential definition of 
remission in SLE has the greatest validity.  
 
Other points of discussion.  
Patient’s Global Assessment. There was controversy about the role of the Patient’s Global 
Assessment (PGA) in a remission definition. A majority felt that PGA cannot currently be included 
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pending further research, and specifically that such research is needed to validate PGA as an 
outcome in reference to remission. Many felt that a better instrument to capture the patient’s 
perspective may be needed. However, patient representatives (authors KL, CC, BvL) were concerned 
that the patient perspective was omitted. Indeed, in the T2T recommendations for SLE, both 
overarching principles and specific recommendations advocate including the patient’s perspective in 
decision-making. However, there is no fully validated measure for the patient’s perspective at this 
time. It was remarked that the PhGA can reflect patient perspective, and it was proposed to 
emphasize that PhGA should pay careful attention to patient symptoms, or conversely, that PGA 
could be a longer-term outcome used in the testing of remission definitions; but in formal votes no 
consensus was reached on these points.  
Inclusion of validated skin score. The dermatologists in the task force (authors AK and VPW) 
suggested to supplement the definition of remission with a validated skin score. 
Definition based only on symptoms. A rheumatologist (author MW) pointed out that in as much as 
the task force is developing possible definitions of remission, a definition based only on symptoms 
and without the use of an index could also be tested. 
Plans for further work and research agenda. The task force agreed upon a plan of work that would 
include the use of longitudinal datasets from clinical trials, observational studies, registries etc. to 
test each of the definitions of remission. Likewise, definitions of remission “on treatment” and “off 
treatment” will be tested separately against the pre-specified dependent outcomes indicated above, 
and different durations of these definitions will also be tested. Moreover, studies done on patients 
“off treatment” will also record the use of antimalarials and analyze the extent to which this makes a 
difference. As always, findings in such subanalyses may inform future changes in the proposed 
definitions. 
Proposed durations to be analyzed include 6 months, 12 months, 2 years, and 5 years.  
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In addition to this continued work, the task force also recommends specific research to investigate 
whether definitions of remission are applicable irrespective of genetic backgrounds and/or ethnicity. 
 
 
Discussion 
An international task force consisting of patient representatives and specialists in clinical 
immunology, dermatology, nephrology and rheumatology was convened and achieved high-level 
agreement on eight statements, three key principles, and a set of outcomes relating to remission in 
SLE, thereby providing a road-map for further work towards a generally applicable definition.  
Remission was approached as a global state, whereas it is recognized that remission can be defined, 
and has in some instances been defined, at the individual organ system level.  
As a conceptual starting-point remission was identified as a desirable outcome for patients with SLE 
with at the very least the absence of major symptoms and signs of SLE. Remission is considered 
distinct from a cure and it is also regarded as meaningfully different from a state of low disease 
activity in SLE such as the lupus low disease activity state (LLDAS) that has recently been 
developed by the Asia-Pacific Lupus Collaboration.[5] However, the latter definition does not solely 
require the presence of low disease activity and does therefore, in fact, include both patients who 
have a low level of disease activity and also those who are in remission.  
Perhaps most critically for future work in this area, it is recognized that remission has to be a state 
that, if sustained, is associated with a low likelihood of adverse outcome.  
Regarding treatment, there was consensus that treatment with antimalarials does not preclude the 
patient from being considered to be in remission, in respect of the recommendation that anti-
malarials should be considered as long-term maintenance therapy for patients with SLE even if they 
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have achieved remission.[3] It was also agreed upon by all that patients who are treated with 
moderate- or high-dose glucocorticoids cannot be considered to be in remission even if they would 
fulfill other criteria for remission. It is well established that glucocorticoids may suppress signs of 
disease, but will not achieve bona fide disease control, and also constitute one of the major risk 
factors for negative outcomes in SLE. 
In contrast to these areas of agreement, no consensus could be achieved on two important issues.  
First, it transpired that the inclusion of ‘duration’ in a definition of remission was controversial. 
Some argued that definitions of remission in other disease areas do not have this requirement, and 
that utility of a definition in clinical studies including clinical trials will be significantly limited if 
duration is explicitly required. Others argued that remission achieved on only one given point in time 
lacks clinical relevance in a disease that can be relapsing and remitting. Following lengthy 
discussion, the task force was able to agree on a compromise using the wording “Remission is a 
durable state characterized by ....” and also clearly identified the need for studies linking the duration 
of any definition of remission with longer-term outcomes.  
Second, the task force did not agree on the precise role of the Patient Global Assessment (Patient 
GA) in a remission definition. This issue was debated at considerable length. Several task force 
members including patient representatives were concerned that the patient perspective was not 
explicitly included in the definition, and emphasized the importance of a definition of remission that 
‘resonates’ with the patient. However, a majority of the task force felt that while the patient’s 
perspective is critically important in the patient-physician interaction, when it comes to a definition 
of remission for the purposes of clinical and epidemiological studies and clinical trials more work is 
needed in order either to validate Patient GA as an outcome,or more likely to develop a better 
instrument to capture the patient’s perspective. It was pointed out that the physician, when assessing 
disease activity, is expected to weigh in the patient’s perspective.  
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Additionally, the task force agreed on the definition of “serological activity” but no consensus was 
reached regarding whether the latter should be taken into account to define remission. The task force 
agreed upon the use of longitudinal datasets to determine whether serology adds to the construct 
validity of each definition. 
Nomenclature for remission in SLE was extensively discussed. Many terms were proposed, 
including  “complete remission”, “partial” remission”, “clinical remission”, “serological remission”, 
“lupus under control”, “inactive disease” etc., many of which were overlapping. In order to simplify 
matters and achieve consistency the task force recommends that only one distinction is made 
between “remission off therapy” and “remission on therapy”, where “off-therapy” must mean that 
the patient is on no systemic treatments for SLE other than anti-malarials. While “remission-on-
antimalarials-only” would be the most accurate term for this state, “remission off-therapy” was 
chosen for brevity and convenience, even though it does allow antimalarial therapy. As stated 
previously, it will be necessary in future studies to account for the actual use of antimalarials in this 
group of patients, and subsequent analyses of patients who are and who are not on antimalarials may 
lead to further distinctions in these categories.  
 “Remission-on-therapy” will allow stable immunosuppressives, including biologics, and low-dose 
glucocorticoids. It is of interest to note that the latter type of definition is the more usual in other 
autoimmune diseases, such as RA and Crohn’s disease, and would also allow investigators to use the 
definition in clinical trials.  
One limitation of the approach taken by the task force is the decision to limit serological activity to 
anti-DNA antibodies and low complement. Recent research shows the importance of antibodies to 
RNA binding proteins (RBPs) to the formation of immune complexes that can stimulate interferon 
production.  Further research may show that, unless these antibodies are assayed, the serological 
assessment is incomplete.   
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Finally, the task force recommends a clear research agenda of testing the construct validity of 
potential remission definitions against death, damage, lupus flares, and HR-QOL measures as 
outcomes (dependent variables) in suitable cohorts of patients. Several task force members have 
conducted or are conducting such studies. This approach will establish which definition(s) of 
remission in SLE optimally identifies patients with a better disease course in these four outcomes. 
 
In summary, a set of statements and key principles relevant to remission in SLE were 
established by an international task force. This work provides a pathway for testing individual 
definitions against longer-term outcomes in order to arrive at a definition of remission in SLE.  
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